Irritable bowel syndrome (IBS) is the most prevalent functional gastrointestinal (GI) disorder, affecting 10–15% of the population worldwide. Based on the associated bowel dysfunction, IBS is categorized as diarrhea (IBS‐D), constipation (IBS‐C), or alternating (IBS‐M). The analysis of bowel dysfunction is primarily based on the patients' response to the physicians’ questions. However, this does not help to evaluate the severity of bowel dysfunction.
Various biomarkers are available for IBS such as combination panels of serological markers, markers of inflammation, fecal or biopsy markers (such as chromogranin), brain imaging or measurement of colonic transit. They often differentiate IBS from inflammatory bowel disease (IBD) or celiac disease, but they do not necessarily evaluate the severity of the disorder. A study was conducted to identify biomarkers that would be clinically…
